RT Journal Article
SR Electronic
T1 The evaluation of medication adherence in patients with pulmonary thromboembolism
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA3600
DO 10.1183/13993003.congress-2018.OA3600
VO 52
IS suppl 62
A1 Ilknur Basyigit
A1 Serap Argun Baris
A1 Tuba Ciftci
A1 Serhat Ozgun
A1 Hasim Boyaci
YR 2018
UL http://erj.ersjournals.com/content/52/suppl_62/OA3600.abstract
AB Introduction: Pulmonary thromboembolism (PTE) is a disease with high mortality and morbidity, and a risk of recurrence during clinical course. The aim of the study is to evaluate treatment adherence in PTE patients.Method: Morisky treatment adherence questionnaire was performed by phone to PTE patients who had been receiving treatment for the last 3 months.Results: There were 44 (60.3%) female and 29 (39.7%) male. PTE was symptomatic in 76.7% and incidental in 23.3% of the patients. Fifty-three of the patients were using LMWH, 41.1% were receiving rivaroxaban and 5.5% were using warfarin. Sixty patients (82.2%) had high, 8 patients (11%) had intermediate and 5 patients (6.8%) had low adherence. There was no significant difference between genders in terms of having symptomatic or incidental embolism, and treatment adherence. Thirty-eight of the cases (52.1%) were over 65 years old and comorbidities were significantly higher in these patients (p=0.005). There was a significant difference between patients over and under 65 years old in terms of medication used (p=0.009). The most of the patients over 65 years old were using rivaroxaban (55,3%) while there was no patient using warfarin. The mean Morisky questionnaire scores were similar by gender, education level and age limit. However, the mean questionnaire score in symptomatic PTE patients was significantly higher than in incidental PTE cases (p=0,03). Significant differences were also found in symptomatic PTE cases at 2. and 5. questions of questionnaire (p=0.04, p=0.01).Conclusion: Treatment adherence was found to be lower in patients with incidental PTE and it is thought that treatment compliance should be closely monitored especially in this patient group.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, OA3600.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).